The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease (LaCrossE)
Chronic Obstructive Pulmonary Disease
About this trial
This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease focused on measuring Chronic Obstructive Pulmonary Disease (COPD), efficacy, safety, inhalation, long-acting muscarinic receptor antagonist (LAMA)
Eligibility Criteria
Inclusion Criteria:
- A clinical diagnosis of COPD
- FEV1 40 - 80% of the predicted normal value (post-bronchodilator) and post- bronchodilator FEV1/FVC < 70%
Exclusion Criteria:
- Any clinically relevant abnormal findings at screening examinations
- Any clinically significant disease or disorder
Sites / Locations
- Research Site
- Research Site
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Active Comparator
Placebo Comparator
AZD9164 100 mcg First, then Placebo for Spririva
AZD9164 400 mcg First, then Placebo for Spiriva
AZD9164 1200 mcg First, then Placebo for Spiriva
Spiriva 18 mcg First, then Placebo for AZD9164
Placebo for Spiriva First, then Placebo for AZD9164
1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)
1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)